RegenXBio stock analysis
RegenXBio (RB0) Stock Price & Analysis
RB0 Stock Chart & Stats
- Day’s Range
- EUR 7.14 - EUR 7.14
- 52-Week Range
- EUR 4.73 - EUR 13.60
- Previous Close
- EUR 7.43
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 458.32M
- Enterprise Value
- EUR 492.45M
- Total Cash (Recent Filing)
- EUR 250.98M
- Total Debt (Recent Filing)
- EUR 66.55M
- Price to Earnings (P/E)
- ―
- Beta
- 1.46
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- -0.86
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
AAV Platform And Partnerships
REGENXBIO combines an AAV technology platform with internal programs and partner arrangements, creating multiple routes to future revenue. Licensing, milestones, royalties and collaboration payments can diversify commercialization outcomes while extending the platform’s strategic value across serious genetic diseases.
Liquidity And Operating Runway
The reported liquidity position is intended to fund operations through late 2027 under current plans, allowing the company to advance major clinical and regulatory programs without immediate financing pressure. This supports execution through several important milestones and provides greater planning flexibility.
Late-stage Pipeline And Commercial Readiness
Multiple late-stage programs give REGENXBIO several potential paths toward product revenue rather than relying on a single early research asset. Progress toward pivotal readouts, a BLA and commercialization preparation could materially expand the company’s strategic position if clinical and regulatory execution succeeds.
Bears Say
Persistent Losses And Cash Burn
Substantial operating and free-cash-flow deficits show that the current business is consuming capital rather than funding development internally. Continued losses increase dependence on existing liquidity, future financing or partner payments, while potentially limiting flexibility if clinical timelines extend or outcomes disappoint.
RGX-121 Clinical And Regulatory Uncertainty
The RGX-121 clinical hold creates a durable obstacle for a program targeting Hunter Syndrome and leaves its regulatory trajectory unresolved. Ongoing imaging and follow-up may delay development, reduce the program’s near-term contribution, and require management to redirect resources toward other pipeline assets.
Reduced ZOLGENSMA Royalty Protection
Expiration of U.S. ZOLGENSMA intellectual property reduces the geographic coverage of an established royalty stream and increases reliance on other sources such as ITVISMA and future milestones. This can make partner-derived revenue less predictable while internal candidates remain unapproved.
RegenXBio News
RB0 FAQ
What was RegenXBio’s price range in the past 12 months?
What is RegenXBio’s market cap?
When is RegenXBio’s upcoming earnings report date?
How were RegenXBio’s earnings last quarter?
Is RegenXBio overvalued?
Does RegenXBio pay dividends?
What is RegenXBio’s EPS estimate?
How many shares outstanding does RegenXBio have?
What happened to RegenXBio’s price movement after its last earnings report?
Which hedge fund is a major shareholder of RegenXBio?
What is the TipRanks Smart Score and how is it calculated?
RegenXBio Stock Smart Score
Company Description
RegenXBio
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Curran Simpson
- Employees
- 371
- Website
- www.regenxbio.com
- Address
- 9804 Medical Center Drive, Rockville, MD, 20850, US
RegenXBio (RB0) Earnings & Revenues
RB0 Earnings Call
Earnings Call SentimentPositive
The call was strongly optimistic, with extensive progress across sura-vec and RGX-202, encouraging clinical and biomarker data, significant AbbVie milestone funding, a cash runway extending beyond late 2027 milestones, and preparations for potential commercialization. The principal negatives were the unresolved regulatory path for RGX-121, the expiration of U.S. ZOLGENSMA intellectual property, and the fact that major sura-vec and RGX-202 regulatory milestones remain pending.
View all DE:RB0 earnings summariesRB0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 2 | 9 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 8 | 0 | 4 |













